Gene Therapy Shows Promise But Faces Liver Expression Challenges in Primate Studies

Gene therapy using adeno-associated virus (AAV) vectors represents a promising frontier for treating genetic diseases and potentially extending healthy lifespan by addressing root causes of age-related conditions. This technology delivers therapeutic genes directly to cells, offering hope for conditions previously considered untreatable.

Novartis researchers conducted a comprehensive analysis of ten studies involving 51 cynomolgus macaques to understand how AAV9 vectors distribute throughout the body. The primates received various gene therapy formulations through different delivery routes including intravenous injection and spinal fluid administration.

The study revealed consistent delivery of therapeutic genetic material to spinal cord tissues across all delivery methods and timepoints. However, researchers discovered significantly reduced gene expression in liver tissue, regardless of the animal's age, delivery method, or specific genetic construct used. Further investigation using epigenetic profiling revealed that liver cells actively silence the therapeutic genes through molecular mechanisms that prevent their expression.

These findings have important implications for longevity medicine, as many age-related diseases could potentially benefit from gene therapy approaches. Understanding tissue-specific barriers helps researchers design more effective treatments and avoid unexpected therapeutic failures. The liver's role in metabolism, detoxification, and aging makes this discovery particularly relevant for developing anti-aging interventions.

While promising, this research was conducted in non-human primates, and human responses may differ. The study focused specifically on AAV9 vectors, so findings may not apply to other gene therapy approaches currently in development.